The effect of continuous subcutaneous glucose monitoring (CGMS) versus intermittent whole blood finger-stick glucose monitoring (SBGM) on hemoglobin A1c (HBA1c) levels in Type I diabetic patients: a systematic review.

BACKGROUND AND PURPOSE Continuous glucose monitoring (CGMS) is a relatively new technology that measures interstitial glucose every 5 min for 72 h. The resulting profile provides a more comprehensive measure of glycemic excursions than intermittent self-blood finger-stick glucose monitoring (SBGM) and thus could potentially improve diabetes control. We performed a meta-analysis of randomized controlled trials comparing CGMS and SBGM in Type 1 diabetic patients. Our aim was to determine whether CGMS leads to better hemoglobin A1c (HBA1c) levels, a marker of long-term vascular risk. METHODS Randomized controlled trials comparing CGMS and SBGM in Type 1 diabetic patients were identified using both manual and electronic searches of the literature in MEDLINE, EMBASE, PUBMED and Cochrane Central Registry of Controlled Trials from 1996 to March 2007. Relevant studies were independently selected by two reviewers, who also extracted data on study design, quality and effect on HBA1c levels. Data from all trials were pooled using a random effects model. RESULTS Seven studies with a total of 335 patients fulfilled the inclusion criteria. Five studies were confined to the pediatric population (age<18 years). Study duration varied from 12 to 24 weeks. Compared with SBGM, CGMS was associated with a non-significant reduction in HBA1c (0.22%; 95% CI: -0.439% to 0.004%, p=0.055). CONCLUSIONS There is insufficient evidence to support the notion that CGMS provides a superior benefit over SBGM in terms of HBA1c reduction. There was some indication of improved detection of asymptomatic nocturnal hypoglycemia in the CGMS group.

[1]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[2]  Jennifer Y. Liu,et al.  Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. , 2001, The American journal of medicine.

[3]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[4]  Aaron B. Neinstein,et al.  Nocturnal hypoglycemia detected with the Continuous Glucose Monitoring System in pediatric patients with type 1 diabetes. , 2002, The Journal of pediatrics.

[5]  A. Novials,et al.  The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. , 2003, Diabetes care.

[6]  M Hørder,et al.  Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. , 1990, The New England journal of medicine.

[7]  O. Kordonouri,et al.  Assessment of glycemic control by continuous glucose monitoring system in 50 children with type 1 diabetes starting on insulin pump therapy , 2004, Pediatric diabetes.

[8]  W. Tamborlane,et al.  Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. , 2001, Diabetes care.

[9]  E. Lyden,et al.  What is hypoglycemia in patients with well-controlled type 1 diabetes treated by subcutaneous insulin pump with use of the continuous glucose monitoring system? , 2004, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[10]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[11]  Johnny Ludvigsson,et al.  Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. , 2003, Pediatrics.

[12]  Ukpds,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes , 2002 .

[13]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[14]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[15]  J. Silverstein,et al.  Predictors of control of diabetes: monitoring may be the key. , 2004, The Journal of pediatrics.

[16]  A. Moran,et al.  Spurious reporting of nocturnal hypoglycemia by CGMS in patients with tightly controlled type 1 diabetes. , 2002, Diabetes care.

[17]  Sonia Caprio,et al.  Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia? , 2002, Diabetes care.

[18]  Karen Evans.  Factbites200760Factbites. Sydney, Australia: Rapid Intelligence 2005. Gratis Last accessed September 2006 URL: www.factbites.com , 2007 .

[19]  K. Dear,et al.  Continuous Glucose Monitoring–Guided Insulin Adjustment in Children and Adolescents on Near-Physiological Insulin Regimens , 2006, Diabetes Care.

[20]  Claresa Levetan,et al.  Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. , 2004, Mayo Clinic proceedings.

[21]  I. Olkin,et al.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.

[22]  J. Pickup,et al.  Performance assessment of the Medtronic‐MiniMed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in Type 1 diabetic subjects , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[23]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[24]  H. Chase,et al.  Continuous subcutaneous glucose monitoring in children with type 1 diabetes. , 2001, Pediatrics.

[25]  Azadeh Shoaibi,et al.  The public health impact of the MiniMed Continuous Glucose Monitoring System (CGMS)-an assessment of the literature. , 2004, Diabetes technology & therapeutics.

[26]  J. Mastrototaro,et al.  Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. , 1999, Diabetes research and clinical practice.

[27]  Bruce A Buckingham,et al.  Accuracy of the modified Continuous Glucose Monitoring System (CGMS) sensor in an outpatient setting: results from a diabetes research in children network (DirecNet) study. , 2005, Diabetes technology & therapeutics.

[28]  H. Guess,et al.  Continuous subcutaneous glucose monitoring in children with type 1 diabetes mellitus: a single‐blind, randomized, controlled trial , 2006, Pediatric diabetes.

[29]  A. S. Hedayat,et al.  A Unified Approach for Assessing Agreement for Continuous and Categorical Data , 2007, Journal of biopharmaceutical statistics.

[30]  T. Jones,et al.  Subcutaneous glucose sensor values closely parallel blood glucose during insulin‐induced hypoglycaemia , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[31]  A. Schiffrin,et al.  Multiple daily self-glucose monitoring: its essential role in long-term glucose control in insulin-dependent diabetic patients treated with pump and multiple subcutaneous injections. , 1982, Diabetes care.

[32]  M. Hanefeld,et al.  Postprandial glucose regulation and diabetic complications. , 2004, Archives of internal medicine.

[33]  Stuart A Weinzimer,et al.  Analysis of continuous glucose monitoring data from non-diabetic and diabetic children: a tale of two algorithms. , 2003, Diabetes technology & therapeutics.